院外心脏骤停患者脑脊液乳酸水平、脑乳酸代谢与神经功能预后
本回顾性观察研究纳入45例OHCA后复苏并接受目标温度管理的患者,在ROSC后即刻及24、48、72h同步采集CSF与血清测定乳酸。27例(60.0%)3个月神经预后不良(CPC 3-5)。各时间点CSF乳酸在预后不良组均显著高于预后良好组,CSF乳酸预后性能各时点均优于血清乳酸,其中乳酸24h的AUC最高(0.89,95%CI 0.75-0.97)。随时间推移,动-脑脊液乳酸差值(ACDL)在预后不良组下降、在预后良好组上升。
要点
- CSF乳酸24h对3个月不良神经预后预测性能最高,AUC 0.89(95%CI 0.75-0.97),各时点均优于血清乳酸。
- 预后不良组各时点CSF乳酸均显著高于预后良好组(即刻6.97 vs 3.37,24h 4.20 vs 2.10,48h 3.50 vs 2.00,72h 2.79 vs 2.06,均P<0.05)。
- 随时间推移,ACDL在预后不良组从-1.30降至-1.70,在预后良好组从-1.22升至-0.64。
- 研究为单中心回顾性观察,样本量45例,CSF乳酸作为预后标志物需前瞻性验证。
适用人群与场景
- OHCA复苏后存活并接受目标温度管理的患者,ROSC后连续监测CSF与血清乳酸。
诊断标准与关键阈值
- 主要结局为3个月神经预后不良,定义为脑功能分级(CPC)3-5。
- CSF乳酸24h预测不良预后的AUC为0.89(95%CI 0.75-0.97)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性观察研究,单中心,纳入45例OHCA后接受目标温度管理的患者,27例(60.0%)3个月神经预后不良(CPC 3-5)。
- ROSC后即刻、24、48、72h CSF乳酸在预后不良组均显著高于预后良好组(6.97 vs 3.37、4.20 vs 2.10、3.50 vs 2.00、2.79 vs 2.06,均P<0.05)。
- CSF乳酸各时点预后性能均优于血清乳酸,乳酸24h的AUC最高(0.89,95%CI 0.75-0.97)。
- ACDL在预后不良组从-1.30(-2.70-0.77)降至-1.70(-3.2至-0.57),在预后良好组从-1.22(-2.42-0.32)升至-0.64(-2.31-0.15)。
证据类型、等级与局限
- 证据类型:单中心回顾性观察研究。
- 局限:样本量小(45例)、回顾性设计、单中心,原文未报告证据等级或推荐强度。
对床旁实践的改变
- 对于OHCA后接受目标温度管理的患者,ROSC后24h的CSF乳酸可能有助于辅助预测3个月不良神经预后,其判别性能优于同期血清乳酸。
- 该标志物为回顾性单中心小样本结果,不能单独作为决定治疗强度或撤除治疗的依据,需前瞻性验证。
- 原文未提及适用与不适用人群的具体界定,也未给出决策阈值。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Cerebrospinal fluid (CSF) and serum lactate levels were assessed to predict poor neurologic outcome 3 months after return of spontaneous circulation (ROSC). We compared arterio-CSF differences in the lactate (ACDL) levels between two neurologic outcome groups.
METHODS: This retrospective observational study involved out-of-hospital cardiac arrest (OHCA) survivors who had undergone target temperature management. CSF and serum samples were obtained immediately (lactate0), and at 24 (lactate24), 48 (lactate48), and 72 (lactate72) h after ROSC, and ACDL was calculated at each time point. The primary outcome was poor 3-month neurologic outcome (cerebral performance categories 3-5).
RESULTS: Of 45 patients, 27 (60.0%) showed poor neurologic outcome. At each time point, CSF lactate levels were significantly higher in the poor neurologic outcome group than in the good neurologic outcome group (6.97 vs. 3.37, 4.20 vs. 2.10, 3.50 vs. 2.00, and 2.79 vs. 2.06, respectively; all P < 0.05). CSF lactate's prognostic performance was higher than serum lactate at each time point, and lactate24 showed the highest AUC values (0.89, 95% confidence interval, 0.75-0.97). Over time, ACDL decreased from - 1.30 (- 2.70-0.77) to - 1.70 (- 3.2 to - 0.57) in the poor neurologic outcome group and increased from - 1.22 (- 2.42-0.32) to - 0.64 (- 2.31-0.15) in the good neurologic outcome group.
CONCLUSIONS: At each time point, CSF lactate showed better prognostic performance than serum lactate. CSF lactate24 showed the highest prognostic performance for 3-month poor neurologic outcome. Over time, ACDL decreased in the poor neurologic outcome group and increased in the good neurologic outcome group.
参考来源
- Son SH, In YN, Md, et al. Cerebrospinal Fluid Lactate Levels, Brain Lactate Metabolism and Neurologic Outcome in Patients with Out-of-Hospital Cardiac Arrest. Neurocrit Care. 2021. PMID: 33432527. doi:10.1007/s12028-020-01181-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。